GROWTH AND AUTOLOGOUS TUMOR LYSIS BY TUMOR-INFILTRATING LYMPHOCYTES FROM METASTATIC MELANOMA EXPANDED IN INTERLEUKIN-2 OR INTERLEUKIN-2 PLUS INTERLEUKIN-4
Cg. Lindgren et al., GROWTH AND AUTOLOGOUS TUMOR LYSIS BY TUMOR-INFILTRATING LYMPHOCYTES FROM METASTATIC MELANOMA EXPANDED IN INTERLEUKIN-2 OR INTERLEUKIN-2 PLUS INTERLEUKIN-4, Journal of immunotherapy with emphasis on tumor immunology, 14(4), 1993, pp. 322-328
Citations number
20
Categorie Soggetti
Immunology,Oncology,"Medicine, Research & Experimental
Optimal conditions for expanding tumor-infiltrating lymphocytes (TILs)
specifically cytotoxic for autologous melanoma for clinical use have
not yet been identified. In several small studies, interleukin (IL)-4
was reported to promote the growth of such TILs in IL-2. Given the pot
ential implications for TIL therapy, we attempted to confirm these fin
dings in a larger study. Baseline data were first obtained on the prol
iferation, immunophenotype, and cytotoxic reactivity to autologous mel
anoma of TILs cultured in IL-2 alone. Similar studies were performed w
ith TIL cultured concurrently in either IL-2 alone or in a combination
of IL-2 and IL-4. TILs were obtained by excisional biopsy of tumors f
rom 52 patients with metastatic malignant melanoma; TILs from 38 patie
nts were expanded in IL-2 (1,000 U/ml). TILs from 19 biopsies were max
imally expanded 6- to 24,000-fold (median, 300-fold) over 4-10 weeks.
Expansion did not correlate with the weight of, or number of lymphocyt
es in, the biopsy specimen, or the site of the biopsy (lymph node vs.
subcutaneous metastases). During weeks 5-8, TILs from 19 of 25 biopsy
specimens lysed autologous melanoma with little or no lysis of allogen
eic melanoma. Lysis of autologous tumor was blocked by antibody to cla
ss I antigens. Twenty-four TIL specimens were cultured concurrently in
IL-2 alone and in IL-2 plus IL-4 and tested for growth and for lysis
of autologous and allogeneic melanomas. Although in five of 24 culture
s TIL expansion was greater in the combination of IL-2 plus IL-4 than
in IL-2 alone, in 17 of 24 cultures significantly less expansion was o
bserved in the combination than in IL-2 alone (p = 0.037). TILs cultur
ed in IL-2 plus IL-4 displayed enhanced lysis for autologous melanoma
in only three of 19 TIL specimens tested, but were less lytic for auto
logous melanoma in 13 of 19 TIL specimens when compared to TILs grown
in IL-2 alone (p = 0.01). The results show that TILs with preferential
cytotoxic reactivity against autologous melanoma are likely to grow b
etter in IL-2 alone than in IL-2 plus IL-4. Therefore, IL-4 should not
be used for generating TILs for clinical trials of adoptive immunothe
rapy of metastatic melanoma.